C

CSL

Develops and delivers biotherapies and vaccines

Field Medical Lead

Full-TimeDeadline 10/31/26
No salary listed
Expert
Bachelor's, PharmD, PhD, MD
Beijing, China+1 moreMore locations: Shanghai, China
Remote
Biology & Biotech

About the job

Requirements
  • At least 10 years of relevant pharmaceutical or biotherapeutics industry experience.
  • At least 5 years of MSL management experience in comparable companies.
  • Demonstrated ability to organize, prioritize, and work effectively in a dynamic, field-based environment.
  • Demonstrated oral and written communication skills, including communicating and teaching complex scientific information and managing formal and informal scientific conversations and presentations.
  • Ability to travel up to 65%, including weekends, and demonstrate effective virtual communication skills.
  • Experience establishing operational plans for a job area and leading field medical project initiatives.
  • Experience using CRM applications to support coaching and development of an MSL team.
Responsibilities
  • Lead, coach, develop, and retain a high-performing MSL team.
  • Establish field medical objectives and KPIs, and monitor team performance against agreed metrics.
  • Conduct regular field coaching, performance reviews, and capability development activities.
  • Identify and address MSL training, compliance, and professional development needs.
  • Ensure onboarding and integration of new MSL team members.
  • Lead the development and execution of field medical plans aligned with affiliate and global Medical Affairs strategy.
  • Oversee the creation and implementation of KOL engagement plans and MSL plans of action.
  • Cascade strategic priorities and medical objectives to the field team and ensure execution excellence.
  • Partner with Medical Affairs leadership to support annual planning, budget management, and resource allocation.
  • Ensure high-quality, compliant scientific engagement with Thought Leaders, HCPs, professional societies, and other stakeholders.
  • Support MSLs in building and maintaining strategic relationships with key external experts.
  • Monitor progress and quality of KOL engagement activities and optimize plans based on emerging needs and opportunities.
  • Collaborate with key thought leaders and internal stakeholders at country, regional, and global levels.
  • Ensure high-quality CRM documentation and utilization to support insight generation.
  • Aggregate and analyze field medical insights, identify emerging scientific trends, barriers to care, and evidence gaps.
  • Communicate actionable insights to local, regional, and global Medical Affairs teams to inform strategy and decision-making.
  • Support participation in Medical Affairs Strategy Team activities and planning processes.
  • Contribute to evidence-generation planning by aggregating field intelligence and identifying knowledge gaps.
  • Support feasibility assessment and execution of local evidence-generation initiatives where appropriate.
  • Ensure MSL awareness of and compliance with Investigator-Initiated Study processes and areas of scientific interest.
  • Support dissemination of scientific publications and ensure MSL proficiency in communicating emerging data and evidence.
  • Provide field insights to support development of medical content, scientific narratives, and educational materials.
  • Lead field medical preparation and execution for key scientific congresses and medical meetings.
  • Coordinate MSL participation in congress coverage, scientific debriefs, and insight collection activities.
  • Ensure effective dissemination of congress learnings and emerging scientific information across relevant stakeholders.
  • Ensure field medical activities comply with CSL policies, industry codes, and applicable regulations.
  • Ensure MSL understanding of grants governance, Investigator-Initiated Study processes, and medical information procedures.
  • Monitor CRM compliance, documentation quality, and execution of Medical Excellence standards.
  • Identify and escalate issues relating to scientific materials, compliance, or field execution as appropriate.
  • Manage activities within the assigned budget and communicate budget variances.
  • Support vendor oversight to ensure timely, compliant, and cost-effective delivery of services.
  • Ensure health, safety, and security at work in compliance with relevant law, regulation, and company standard operating procedures.
Desired Qualifications
  • A degree in medicine, pharmacy, or an advanced degree in science (PhD or PharmD) with strong relevant field medical experience.
  • Leadership capabilities.
  • A strong technical background with business acumen.
  • Ability to develop expertise in designated therapy areas quickly.
  • Analytical skills and attention to detail.
  • Interpersonal, written, and oral communication skills.
  • Ability to prioritize tasks and meet agreed metrics with customer focus.
  • Ability to work autonomously with manager support and collaboratively as part of a brand team.
  • Ability to show initiative and sound judgment.
  • Expert knowledge of the Medical Affairs Code of Conduct.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.